Skip to search formSkip to main contentSkip to account menu

MK 0431

Known as: 0431, MK, MK-0431, MK0431 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
OBJECTIVE Treatment of NOD mice with the dipeptidyl peptidase-IV (DPP-IV) inhibitor sitagliptin preserved islet transplants… 
Highly Cited
2009
Highly Cited
2009
OBJECTIVE—The endopeptidase dipeptidyl peptidase-IV (DPP-IV) has been shown to NH2-terminally truncate incretin hormones, glucose… 
Highly Cited
2008
Highly Cited
2008
OBJECTIVE—Dipeptidyl peptidase-IV (DPP-IV) inhibitors have been introduced as therapeutics for type 2 diabetes. They partially… 
Highly Cited
2007
Highly Cited
2007
Sitagliptin (MK‐0431) is an orally active, potent, and selective dipeptidyl peptidase‐4 inhibitor used for the treatment of… 
Highly Cited
2006
Highly Cited
2006
Aims/hypothesisThe aim of this study was to assess the efficacy and safety of sitagliptin (MK-0431) as monotherapy in patients… 
Review
2006
Review
2006
  • A. Barnett
  • International journal of clinical practice
  • 2006
  • Corpus ID: 2645092
The dipeptidyl peptidase 4 (DPP‐4) inhibitors enhance the body's own ability to control blood glucose by increasing the active… 
Highly Cited
2006
Highly Cited
2006
Sitagliptin (MK‐0431) is an oral, potent, and selective dipeptidyl peptidase‐IV (DPP‐4) inhibitor developed for the treatment of… 
Highly Cited
2005
Highly Cited
2005
A novel series of beta-amino amides incorporating fused heterocycles, i.e., triazolopiperazines, were synthesized and evaluated…